Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Atara Biotherapeutics, Inc. - Common Stock
(NQ:
ATRA
)
4.415
-1.465 (-24.91%)
Streaming Delayed Price
Updated: 3:21 PM EST, Jan 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atara Biotherapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
↗
January 03, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
↗
January 05, 2023
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
↗
December 24, 2022
The attraction of all three biotech stocks is their potential.
Via
The Motley Fool
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
December 20, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
December 20, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday
↗
December 20, 2022
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!
Via
InvestorPlace
Atara Biotherapeutics Announces Changes to Its Board of Directors
December 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
December 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
November 23, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
↗
November 11, 2022
Gainers
Via
Benzinga
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
↗
November 10, 2022
Gainers
Via
Benzinga
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
November 09, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
November 08, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics's Earnings: A Preview
↗
November 07, 2022
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Atara...
Via
Benzinga
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
November 01, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
October 26, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Moderna, Amazon, Tesla, And Other Big Gainers From Friday
↗
October 24, 2022
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
↗
October 24, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
Via
Benzinga
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
October 14, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact
↗
September 29, 2022
Via
Benzinga
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
↗
September 29, 2022
Gainers Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European...
Via
Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
↗
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
September 28, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
